Envista Holdings Corp

Envista Holdings Corp(NVST)股票分析

$23.500

+0.700 (+2.98%)收盤時

Loading chart…
最高
23.515
開盤
22.500
成交量加權均價
23.17
成交量
3.67M
市值
2.83B
最低
22.500
成交金額
85.12M
企業價值/稅息折舊攤銷前利潤(TTM)
8.91

Envista Holdings Corporation provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a provider of a range of solutions to support dental implants, orthodontic treatments, dental diagnostics, general dental consumable products, equipment and services. Its segments include Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.

AI 分析 of Envista Holdings Corp (NVST)

持有

Envista Holdings Corp is currently trading at $23, which is below the consensus analyst price target of $31.32, suggesting potential upside of approximately 36.5%. However, the stock has a low RSI of 36.651, indicating it may be oversold, and recent downgrades from analysts could pose risks. The main risk is the expected $10 million revenue headwind in Q3 due to inventory adjustments, which may impact short-term performance.

估值指標

Envista Holdings Corp(NVST)目前預期本益比為 16.81,5 年平均預期本益比為 19.81。

預期本益比

合理
5 年均值 P/E
19.81
目前P/E
16.81
高估
23.71
低估
15.92

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
12.22
目前EV/EBITDA
8.91
高估
14.34
低估
10.09

預期股價營收比

合理
5 年均值 P/S
1.75
目前P/S
1.23
高估
2.30
低估
1.20

Alphio AI 對 NVST 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NVST

$18.76

情境價格

基

基準

基準 · 50%NVST

$17.69

情境價格

悲

悲觀

悲觀 · 25%NVST

$15.35

情境價格

持有 NVST 的大戶

A

Asahi Life Asset Management Co.,Ltd.

+ 持有NVST

-0.56%

3個月報酬率

I

Ilex Capital Partners (Uk) LLP

+ 持有NVST

-0.58%

3個月報酬率

A

ArrowMark Colorado Holdings, LLC

+ 持有NVST

-2.31%

3個月報酬率

A

Ariel Investments, LLC

+ 持有NVST

-3.36%

3個月報酬率

I

Integral Health Asset Management, LLC

+ 持有NVST

-6.42%

3個月報酬率

D

Deerfield Management Company, L.P.

+ 持有NVST

-6.90%

3個月報酬率

事件時間軸

2026-10-15 (ET)

08:30:00

Kerr Dental Launches ZenFlex RT Rotary Retreatment Files

2026-09-03 (ET)

16:30:00

Major Averages Close Sharply Higher, Nasdaq Up 1.40%

12:00:00

Major Averages Surge at Noon, Nasdaq Up 1.34%

2026-08-05 (ET)

16:30:00

Company Reports Q2 Revenue of $731M, Exceeds Expectations

16:30:00

Raises 2026 Revenue Growth Outlook to 3.5%-4.5%

資訊

NVST 常見問題 —— 由 Alphio AI 解答

Envista Holdings Corporation provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a provider of a range of solutions to support dental implants, orthodontic treatments, dental diagnostics, general dental consumable products, equipment and services. Its segments include Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).

Envista Holdings Corp is currently trading at $23, which is below the consensus analyst price target of $31.32, suggesting potential upside of approximately 36.5%. However, the stock has a low RSI of 36.651, indicating it may be oversold, and recent downgrades from analysts could pose risks. The main risk is the expected $10 million revenue headwind in Q3 due to inventory adjustments, which may impact short-term performance.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易